Policy Briefings

Minaris Expands Philadelphia Viral Clearance Labs

Halo Pharma to Operate as Stand-Alone CDMO Following Noramco Sale

Siegfried Agrees Acquisition of Noramco Drug Substance Business

Bora Biologics Opens $30M Expanded GMP Manufacturing Facility in San Diego

Catalent Plans Closure of Belgium Cell Therapy Site

Eurofins CDMO Alphora Adds AI-driven Tool to Solid-State Screening Programs

Recipharm Opens Dedicated Facility for Non-Bacterial Beta-Lactam Manufacturing

HanchorBio Signs Strategic Development and Manufacturing Pact with WuXi Biologics

ST Pharm Secures $56m API Contract for Oligonucleotide Therapy

SK Bioscience to Support Manufacturing and Development of Updated Zaire Ebolavirus Vaccine

NorthX Biologics Joins Diamyd Medical and APL in Long-Term Retogatein Collaboration

Pluri Completes First Phase of Resbiomed Programme

SpectronRx Expands Grissom Aeroplex to 200,000 Sq Ft of GMP Radiopharmaceutical Capacity

Alivus Life Sciences Posts 36.4% EBITDA Margin as CDMO Business Recovers

Gannet BioChem Acquires Laysan Bio to Expand Activated Polymer Capabilities

Samsung Biologics Reports KRW 4,557 Billion (USD 3.5 billion) Revenue for FY 2025

Charles River Partners with Gazi University on Gene Therapy CDMO Collaboration

Vetter Earns EcoVadis Platinum Rating and SBTi Validation for Emissions Targets